Lifeboat Foundation

Year 2014 face_with_colon_three Basically the whole bodies cells could be a pacemaker enabling even immortality with electricity at low voltage.

In pigs, scientists have succeeded in turning cardiac muscle cells into specialized pacemaker cells. Such technology could eventually replace electronic pacemakers, researchers say.

Continue reading “Reprogramming Cells for a Bio-Pacemaker” »

After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way.

On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older.

It could be available for seniors as soon as this fall, pending a recommendation for its use from the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, which next meets in June.

A deep slumber might help buffer against memory loss for older adults facing a heightened burden of Alzheimer’s disease, new research from the University of California, Berkeley, suggests.

Deep sleep, also known as non-REM slow-wave sleep, can act as a “cognitive reserve factor” that may increase resilience against a protein in the brain called beta-amyloid that is linked to memory loss caused by dementia. Disrupted sleep has previously been associated with faster accumulation of beta-amyloid protein in the brain. However, the new research from a team at UC Berkeley reveals that superior amounts of deep, slow-wave sleep can act as a protective factor against memory decline in those with existing high amounts of Alzheimer’s disease pathology —a potentially significant advance that experts say could help alleviate some of dementia’s most devastating outcomes.

“With a certain level of brain pathology, you’re not destined for cognitive symptoms or memory issues,” said Zsófia Zavecz, a postdoctoral researcher at UC Berkeley’s Center for Human Sleep Science. “People should be aware that, despite having a certain level of pathology, there are certain lifestyle factors that will help moderate and decrease the effects.

SOUTHWEST FLORIDA — Robots are part of everyday life. They build cars, protect us and some even train us.

“Rosie the Riveter” has become “Rosie the Robot.”

But what about a robotic device that scrubs in to the operating room? NBC2 anchor Lisa Spooner found out how metal meets medical.

Not just mice anymore. The eyes of primates made young.

A Harvard study found that a new gene therapy that reprograms cells to their younger state can reverse NAION-caused vision loss in primates.

Researchers at the Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute at the Cleveland Clinic in Ohio have authored a case report on the positive effects of psilocybin on color blindness.

Published in the journal Drug Science, Policy and Law, the researchers highlight some implications surrounding a single reported vision improvement self-study by a colleague and cite other previous reports, illustrating a need to understand better how these psychedelics could be used in therapeutic settings.

Past reports have indicated that people with color vision deficiency (CVD), usually referred to as color blindness, experience better color vision after using lysergic acid diethylamide (LSD) or psilocybin (magic mushrooms). There is a lack of scientific evidence for these claims, as researching the effects of these drugs has been highly restricted.

https://youtube.com/watch?v=KSDhqhKL-JQ

Sound waves can cross the blood-brain barrier and could deliver chemotherapy to complex and treatment-resistant glioblastomas.

High-grade gliomas functionally remodel neural circuits in the human brain, promoting tumour progression and impairing cognition.

CHICAGO, May 3 (Reuters) — An experimental Alzheimer’s drug developed by Eli Lilly and Co (LLY.N) slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease.

Lilly’s drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer’s by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer’s proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death.

The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB).